Research Highlights |
Featured
-
-
News |
Liver-disease mutation corrected in human stem cells
Patient-derived stem cells reprogrammed to become healthier.
- Susan Young
-
News |
Vaccine campaign to target deadly childhood diarrhoea
Programme to guard against second-biggest killer of under-fives rolls out across Africa.
- Declan Butler
-
Letter |
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis
- Claudia Günther
- , Eva Martini
- & Christoph Becker
-
Letter |
Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors
- Sayaka Sekiya
- & Atsushi Suzuki
-
Review Article |
Genetics and pathogenesis of inflammatory bowel disease
- Bernard Khor
- , Agnès Gardet
- & Ramnik J. Xavier
-
Review Article |
Intestinal homeostasis and its breakdown in inflammatory bowel disease
- Kevin J. Maloy
- & Fiona Powrie
-
-
Outlook |
Perspective: Miles to go before we sleep
New drugs are generating much excitement, but a cure for all will take generations of therapies, argues Charles Rice
- Charles Rice
-
Outlook |
Perspective: Recognizing resistance
The hepatitis C virus is endemic among injection drug users, who could harbour treatment-resistant viruses. We need to adapt to this reality, says Diana Sylvestre
- Diana Sylvestre
-
Outlook |
Pharmacogenomics: Playing the odds
Can doctors calculate a patient's chance of being cured by searching their DNA? Hepatitis C researchers are starting to make this a reality.
- Amy Maxmen
-
Outlook |
Introduction: A smouldering public-health crisis
Long overshadowed by HIV, the hepatitis C virus is starting to take its toll. And the heat is on to find and treat those affected.
- Lauren Gravitz
-
Outlook |
Global health: A uniquely Egyptian epidemic
Egypt has the highest prevalence of hepatitis C worldwide. And the epidemic will soon peak. Prevention demands political will, ample funding and a change in mindset.
- Mohammed Yahia
-
Outlook |
Therapeutics: New drugs hit the target
With two recently approved drugs and dozens more in the pipeline, hepatitis C treatment will improve over the next decade.
- Jana Schlütter
-
Outlook |
Vaccines: A moving target
The hepatitis C virus has a set of cunning ways to evade immunity, but researchers are turning the immune system on it.
- Michael Eisenstein
-
Outlook |
Diagnostics: A testing journey
Results ready in minutes and more efficacious drugs will help find and treat the hundreds of millions of carriers.
- Sarah DeWeerdt
-
Letter |
A genetically humanized mouse model for hepatitis C virus infection
- Marcus Dorner
- , Joshua A. Horwitz
- & Alexander Ploss
-
News & Views |
The sound of silence
There are various ways in which apparently 'silent' DNA mutations — those that don't result in a change in the encoded protein — have untoward consequences. A striking example has emerged in a study of Crohn's disease.
- Laurence D. Hurst
-
News & Views |
Context is key in the gut
The vitamin-A metabolite retinoic acid normally favours immune tolerance in the gut. But in coeliac disease — an intestinal inflammatory disorder due to adverse reactivity to a dietary protein — it may do just the opposite. See Letter p.220
- Craig L. Maynard
- & Casey T. Weaver
-
News Explainer |
Is breast not best for babies?
New evidence contradicts World Health Organization breastfeeding advice.
- Natasha Gilbert
-
News & Views |
Genomic evolution of metastasis
Prognosis for patients with pancreatic cancer is bleak, often owing to late diagnosis. The estimate that at least 15 years pass from tumour initiation to malignancy offers hope for early detection and prevention. See Letters p.1109 & p.1114
- E. Georg Luebeck
-
News & Views |
Genes, viruses and microbes
Variations in several genes can increase an individual's susceptibility to complex disorders. But what tips the balance to cause the full-blown disease? For Crohn's disease, viruses could provide part of the answer.
- Alison Simmons
-
Research Highlights |
Immunology: Gene plus virus
-
News & Views |
An unsuspected drug target
Infection with hepatitis C is one of the main causes of liver disease, yet there are no broadly effective treatments. Discovery of a potent inhibitor of this virus shows that researchers must think outside the box.
- Catherine L. Murray
- & Charles M. Rice
Browse broader subjects
Browse narrower subjects
- Anal diseases
- Biliary tract disease
- Dysbiosis
- Enteric neuropathies
- Functional gastrointestinal disorders
- Gastroenteritis
- Gastrointestinal bleeding
- Gastrointestinal cancer
- Hepatitis
- Inflammatory bowel disease
- Intestinal diseases
- Liver diseases
- Motility disorders
- Nutrition disorders
- Oesophageal diseases
- Pancreatic disease
- Stomach diseases
- Ulcers